Takhzyro (lanadelumab) is a medicine for the prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is available as solution for injection in single-dose, ready-to-use vial.
Takhzyro (lanadelumab) is a medicine for the prevention of recurrent attacks of hereditary angioedema (HAE) in patients aged 12 years and older. It is available as solution for injection in single-dose, ready-to-use vial.
